Last reviewed · How we verify
PF-06946860
At a glance
| Generic name | PF-06946860 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue (PHASE2, PHASE3)
- A Study of Ponsegromab in People With Heart Failure (PHASE2)
- Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia (PHASE1)
- Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. (PHASE1)
- Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants (PHASE1)
- Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06946860 CI brief — competitive landscape report
- PF-06946860 updates RSS · CI watch RSS
- Pfizer portfolio CI